Compare · ABT vs DCOY
ABT vs DCOY
Side-by-side comparison of Abbott Laboratories (ABT) and Decoy Therapeutics Inc. (DCOY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and DCOY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $182.59B, about 105963.7x DCOY ($1.7M).
- Over the past year, ABT is down 20.0% and DCOY is down 95.3% - ABT leads by 75.3 points.
- Both names hit the wire about 10 times in the past 4 weeks.
- ABT has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Abbott Laboratories
- Decoy Therapeutics Inc.
- Price
- $105.58-2.49%
- $2.65-8.30%
- Market cap
- $182.59B
- $1.7M
- 1M return
- -2.07%
- -36.30%
- 1Y return
- -20.02%
- -95.32%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2015
- News (4w)
- 10
- 10
- Recent ratings
- 25
- 1
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
- VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)
- EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)
- Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
- CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)
- Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
Latest DCOY
- Director Lieber Jonathan I was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Chief Business Officer Marschel Peter Klaus was granted 3,900 shares (SEC Form 4)
- Chief Executive Officer Pierce Frederick Ii was granted 33,455 shares, increasing direct ownership by 2,409% to 34,844 units (SEC Form 4)
- Chief Financial Officer Rosenblum Mark J was granted 9,682 shares, increasing direct ownership by 576% to 11,363 units (SEC Form 4)
- Chief Scientific Officer Hibner Barbara Louise was granted 4,216 shares (SEC Form 4)
- Director Hanish Arnold C was granted 3,000 shares, increasing direct ownership by 718% to 3,418 units (SEC Form 4)
- Director Lammers Paul was granted 2,000 shares, increasing direct ownership by 200,000% to 2,001 units (SEC Form 4)
- Director Burleson Tess was granted 2,000 shares, increasing direct ownership by 100,000% to 2,002 units (SEC Form 4)
- Director Mcvicar William K. was granted 3,000 shares, increasing direct ownership by 150,000% to 3,002 units (SEC Form 4)
- Director Gauthier Patricia G. was granted 2,000 shares (SEC Form 4)